RT Journal Article SR Electronic T1 A machine-learning evaluation of biomarkers designed for the future of precision medicine JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.07.09.23292430 DO 10.1101/2023.07.09.23292430 A1 Climer, Sharlee YR 2023 UL http://medrxiv.org/content/early/2023/07/12/2023.07.09.23292430.abstract AB Precision medicine is cognizant of the impact of genetics and environments on subtypes of heterogeneous diseases and aims to identify, diagnose, and treat each subtype appropriately. Real-valued biomarkers, such as protein levels in plasma, are key for practical subtype diagnoses and hold potential to elucidate subtypes and illuminate promising drug targets. Biomarkers that are common across all subtypes have been discovered using fold change (FC) and the area under the receiver operating characteristic curve (AUC). However, FC and AUC fail to identify biomarkers for subtypes when they comprise less than half of the disease group. We present here a machine-learning biomarker evaluation method based on clustering of the data points, referred to as Difference in Bicluster Distances (DBD). We contribute efficient, yet optimal, software coupled with rigorous validation techniques, and demonstrate our approach on a late-onset Alzheimer disease (AD) gene expression dataset. Our trials produced four significant genes and appropriate thresholds for biomarker diagnostics. While none of these genes were identified as significant by either FC or AUC for the given dataset, the genes have been independently associated with AD or neurological disorders by other groups using completely independent means. In summary, DBD provides a unique and effective method for screening real-valued data to identify biomarkers associated with subtypes of heterogeneous diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAlzheimer's Association (AARG-22-925002) and research grants from the University of Missouri - St. LouisAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15222I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yeshttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15222 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15222